Sage Therapeutics, Inc. (NASDAQ:SAGE) had its price target upped by Raymond James Financial, Inc. to $109.00 in a research note published on Thursday. They currently have a buy rating on the biopharmaceutical company’s stock.

A number of other research firms have also weighed in on SAGE. Leerink Swann boosted their price objective on Sage Therapeutics from $85.00 to $123.00 and gave the stock a positive rating in a research note on Thursday. Royal Bank Of Canada boosted their price objective on Sage Therapeutics to $145.00 and gave the stock an outperform rating in a research note on Thursday. Stifel Nicolaus boosted their price objective on Sage Therapeutics from $91.00 to $105.00 and gave the stock a buy rating in a research note on Thursday. Cowen and Company lowered their price objective on Sage Therapeutics from $100.00 to $90.00 and set an outperform rating on the stock in a research note on Tuesday, September 12th. Finally, J P Morgan Chase & Co lowered their price objective on Sage Therapeutics from $99.00 to $85.00 and set an overweight rating on the stock in a research note on Tuesday, September 12th. Three equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of Buy and a consensus price target of $99.86.

Sage Therapeutics (NASDAQ SAGE) traded down $0.61 during midday trading on Thursday, reaching $96.04. The company’s stock had a trading volume of 1,750,000 shares, compared to its average volume of 524,206. Sage Therapeutics has a one year low of $44.55 and a one year high of $98.80.

Sage Therapeutics (NASDAQ:SAGE) last released its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.97) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.98) by $0.01. The firm’s quarterly revenue was up .0% on a year-over-year basis. equities analysts forecast that Sage Therapeutics will post -7.36 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Sage Therapeutics, Inc. (SAGE) PT Raised to $109.00 at Raymond James Financial, Inc.” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright & trademark law. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/11/13/sage-therapeutics-inc-sage-pt-raised-to-109-00-at-raymond-james-financial-inc.html.

Hedge funds have recently bought and sold shares of the stock. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Sage Therapeutics by 11.1% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,378 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 138 shares during the period. Hershey Trust Co. purchased a new stake in shares of Sage Therapeutics in the 3rd quarter valued at $118,000. Turner Investments LLC purchased a new stake in shares of Sage Therapeutics in the 2nd quarter valued at $159,000. Dubuque Bank & Trust Co. purchased a new stake in shares of Sage Therapeutics in the 2nd quarter valued at $167,000. Finally, Canada Pension Plan Investment Board purchased a new stake in shares of Sage Therapeutics in the 2nd quarter valued at $175,000.

About Sage Therapeutics

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Analyst Recommendations for Sage Therapeutics (NASDAQ:SAGE)

Receive News & Stock Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related stocks with our FREE daily email newsletter.